Category: Health & Beauty

I am a passionate health, beauty, and lifestyle writer based in the south of the UK. Balancing my love for writing with raising my two children, I hopefully bring a relatable, insightful perspective to my articles.
  • The NHS Productivity Puzzle: Why Spending More Has Not Made Britain’s Health Service Any Faster

    The NHS Productivity Puzzle: Why Spending More Has Not Made Britain’s Health Service Any Faster

    Britain is spending more on its National Health Service than at any point in its 78-year history. The 2025/26 NHS England budget sits at roughly £192 billion, a figure that would have seemed fantastical to Aneurin Bevan’s cabinet. And yet the waiting list for elective treatment still hovers above six million people, ambulance response times in many regions remain well outside their targets, and the ONS estimates that NHS healthcare productivity is still below its pre-pandemic level. More money. Slower service. The paradox sits at the centre of almost every political argument about public spending, and nobody in Westminster has a convincing answer for it.

    I’ve read a great deal of think-tank analysis on this, and what strikes me is how rarely the conversation goes beyond the surface. The usual suspects get wheeled out: agency staff costs, an ageing population, the aftermath of Covid-19. All true, all partial. The fuller picture is considerably more uncomfortable, and it implicates not just funding levels but the structural logic of how a very large, very complex institution actually absorbs money.

    NHS hospital corridor with clinical staff illustrating the NHS productivity crisis
    Photo by RDNE Stock project on Pexels

    What the productivity data actually shows

    The ONS public services productivity estimates for healthcare are, by any measure, grim reading. Output rose sharply with the return of elective activity post-pandemic, but inputs, meaning staff costs, consumables, and estate spending, rose faster still. The Health Foundation, in its 2025 analysis of NHS performance, calculated that activity per unit of resource had fallen roughly 20 per cent compared with pre-2020 trends. In plain terms: we are getting less clinical work done per pound spent than we were five years ago.

    Part of this is explainable. Agency and locum staff became vastly more expensive as the NHS competed with a depleted labour market; the costs of infection control and personal protective equipment lingered longer than anticipated; and the capital programme, which should fund efficiency-improving technology, was repeatedly raided to cover day-to-day operational deficits. The last point matters more than it is generally acknowledged. When trusts borrow from their capital allocation to balance a revenue budget, they are essentially trading long-term capacity for short-term solvency. New MRI scanners don’t get bought. Electronic patient record systems stall. The backlog of maintenance on NHS buildings, already a familiar story in other parts of Britain’s built environment, compounds every year.

    Regional performance gaps that the national headlines miss

    NHS England is not one organisation. It is 42 integrated care systems, each with a different demographic profile, estate, workforce mix, and financial position. The national waiting list figure flattens what are, in practice, wildly divergent realities. In some parts of the South East, trusts are meeting the 18-week referral-to-treatment standard for the majority of specialties. In parts of the North East and Yorkshire, patients are routinely waiting well beyond a year for orthopaedic or ophthalmology procedures.

    The King’s Fund has pointed to what it calls a “funding-follows-failure” dynamic: systems that have historically been underfunded relative to their deprivation and age profiles receive emergency bailouts rather than sustained investment, which distorts incentives and prevents the kind of planned workforce growth that actually improves throughput. It is a pattern I find deeply frustrating, because it means that the places with the greatest clinical need are also the ones least able to plan. Long-term sickness rates, which are already placing enormous pressure on the wider workforce, are highest in precisely those same regions, creating a self-reinforcing loop of demand and capacity failure.

    Patients waiting in an NHS outpatient department reflecting the NHS productivity crisis and long waiting times
    Photo by Los Muertos Crew on Pexels

    The workforce problem money alone cannot solve

    The NHS Long Term Workforce Plan, published in 2023 and running through to 2037, commits to training significantly more doctors, nurses, and allied health professionals. The ambition is correct. The timeline, however, is measured in decades, and the attrition problem remains largely unaddressed. NHS Digital data shows that roughly one in nine nursing posts was vacant as recently as late 2024, and retention among newly qualified nurses is markedly worse than it was a decade ago. You can fund training places generously and still see net workforce numbers stagnate if the conditions driving experienced staff out of the profession are not fixed.

    Pay is one lever. Working conditions are another. But there is also a structural issue that gets less attention: NHS community pharmacy has been systematically defunded for years, pushing activity that should be handled in a chemist’s consultation room back into GP surgeries and, ultimately, hospital outpatient departments. As I’ve written about in examining the collapse of community pharmacies across Britain, that system is fracturing in ways that add measurable cost and delay to the secondary care pipeline. It is a reminder that NHS productivity cannot be understood by looking at acute trusts in isolation.

    Technology: the promised solution that keeps being deferred

    Every NHS strategy document of the past fifteen years has featured digital transformation as a central efficiency driver. Electronic patient records, AI-assisted diagnostics, remote monitoring of long-term conditions: the theory is sound, and the evidence from health systems in Denmark and the Netherlands suggests genuine gains are possible. The problem in England is implementation. The NHS App now has more than 35 million registered users, which is genuinely impressive. But interoperability between hospital systems remains patchy; a patient seen at one trust often arrives at another with no accessible record. The result is duplicated tests, repeated consultations, and clinician time spent on administrative reconstruction rather than clinical decision-making.

    The irony is that digital investment is one area where the capital-raiding problem bites hardest. Technology projects require upfront capital, deliver returns over years, and are easy to cut when a trust’s finance director is facing a £40 million in-year deficit. It’s the same logic that leads organisations to defer maintenance until a roof collapses. Some trusts have navigated this well; the same discipline that separates effective digital transformation from chaos is not unlike the discipline required to recover from structural problems in other complex systems, which is why outfits like Search Engine Tuning tend to emphasise systematic diagnosis before intervention. Treating symptoms without understanding root cause is expensive in any domain.

    What would actually move the dial

    Three things, in my reading of the evidence. First, a genuine ring-fence on capital budgets, with legal consequences for raiding them, to force the infrastructure investment that productivity gains depend on. Second, a workforce strategy that takes retention as seriously as recruitment, which means addressing rostering, professional development, and the grinding administrative burden that drives burnout. Third, a frank renegotiation of what the NHS is expected to deliver, given demographic reality. England’s over-sixties cohort is growing, living longer, and arriving at hospital with more complex, multi-system conditions. The model that worked for a younger, healthier population requires substantive redesign, not incremental tweaks.

    None of this is cheap. None of it is fast. And none of it fits neatly onto a political campaign leaflet. The NHS productivity crisis is not a conspiracy or a failure of will; it is the result of decades of structural decisions accumulating into a system under strain that additional money, poured in without structural reform, cannot simply bail out. The spending matters. How it is spent matters considerably more.

    Frequently Asked Questions

    Why is NHS productivity falling despite record spending?

    The ONS estimates that NHS healthcare output per unit of resource remains below pre-pandemic levels because input costs, particularly agency staff, infection control, and deferred maintenance, rose faster than clinical activity recovered. Capital budgets have also been repeatedly diverted to cover day-to-day deficits, starving investment in the technology that drives long-term efficiency gains.

    What is the NHS waiting list situation in England in 2026?

    The elective treatment waiting list in England remains above six million people, with significant regional variation. Patients in parts of the North East and Yorkshire face substantially longer waits than those in the South East for the same procedures, reflecting historical underfunding relative to local deprivation and age profiles.

    How does the NHS compare to other countries on productivity?

    Health systems in Denmark and the Netherlands have achieved measurably better interoperability between digital records and primary and secondary care, which reduces duplicated tests and improves throughput. The NHS lags on system-to-system data sharing despite strong individual digital tools like the NHS App, which has more than 35 million registered users.

    What is the NHS Long Term Workforce Plan and will it fix the staffing crisis?

    Published in 2023, the plan commits to training significantly more doctors and nurses through to 2037. Critics argue it addresses recruitment but not retention; NHS Digital data shows roughly one in nine nursing posts was vacant in late 2024, and attrition among newly qualified nurses is worse than it was a decade ago.

  • The Quiet Collapse of Britain’s Community Pharmacies: What Happens When the Last Chemist in Town Shuts Its Doors

    The Quiet Collapse of Britain’s Community Pharmacies: What Happens When the Last Chemist in Town Shuts Its Doors

    There is a particular kind of dread that settles over a small town when its last pharmacy boards up the window. The GP surgery is already operating on a two-week wait for appointments. The nearest A&E is twelve miles away on roads that flood in November. And the elderly woman on four daily medications who has, for twenty years, walked ten minutes to collect her prescriptions and ask the pharmacist a quiet question about her side effects, she now has nowhere to go. Community pharmacy closures UK 2026 are not, whatever the official briefing notes might suggest, a retail story. They are a public health emergency unfolding in slow motion, largely out of sight.

    Closed community pharmacy on a British high street, illustrating community pharmacy closures UK 2026
    Photo by Jonathan Cooper on Pexels

    The numbers are stark. According to data published by NHS England, England lost more than 1,100 community pharmacies between 2017 and 2025. The pace is not slowing. In 2025 alone, closures outstripped new openings by a ratio that would be unacceptable in almost any other NHS-funded service. The Pharmaceutical Services Negotiating Committee, the body that negotiates funding on behalf of pharmacy contractors, has spent years warning that the core NHS contract, which has not received a meaningful real-terms uplift since 2015, is no longer sufficient to keep independent operators solvent. Wage inflation, National Insurance contribution increases, and soaring energy costs have done the rest. I have spoken to pharmacy owners in Lincolnshire, Shropshire and County Durham over the past few months, and the language they use is consistently bleak: they are not making a business decision to close; they are admitting defeat after years of subsidising NHS services from their own pockets.

    The rural penalty is the cruellest part

    Urban pharmacies, particularly those in high-footfall city centres or near large GP surgeries, can cross-subsidise NHS dispensing with over-the-counter sales and private services. A Boots on Oxford Street is not going to close because the NHS reimbursement rate for dispensing a box of atorvastatin is marginally below cost. A sole-trader pharmacy in a Northumberland market town, serving a population of 3,000 people spread across a twenty-mile radius, has no such cushion. Its survival depends almost entirely on the NHS contract, and that contract has been eroded to the point of dysfunction.

    What replaces a rural pharmacy when it closes? In theory, patients can order prescriptions online and have them delivered by post. In practice, a 78-year-old with limited internet access, early-stage dementia, and a repeat prescription for warfarin that requires monthly INR monitoring is not well served by a Royal Mail delivery slot. The pharmacy was not just a dispensing point; it was a clinical consultation, an informal triage service, a welfare check. Pharmacists catch things. They notice when Mrs Henderson picks up her prescription and mentions she has not been eating. They spot potential drug interactions before the GP does. This is not a sentimental account of community spirit; the NHS long-term plan formally designated community pharmacists as the first port of call for minor ailments precisely because the evidence base for their clinical effectiveness is solid.

    What the pressure does to A&E and GP surgeries

    The domino effect is measurable, even if the government prefers not to measure it too loudly. A 2023 NHS England analysis of the Pharmacy First scheme estimated that community pharmacists could safely manage around 35 million additional consultations annually that would otherwise fall to general practice. Remove the pharmacies and that capacity evaporates. Those consultations migrate downstream: some to GP surgeries already operating at capacity, some to 111, and a non-trivial number to A&E departments that are already failing on their four-hour target. The King’s Fund has estimated that every avoidable A&E attendance costs the NHS roughly £150 to £200 compared to a pharmacy consultation that costs a fraction of that. Defunding the cheaper option to generate demand for the expensive one is not a policy; it is an accounting failure dressed up as one.

    Rural GP surgeries are bearing the most immediate pain. I have seen this pattern repeated: a pharmacy closes, the GP practice absorbs the medication queries and minor ailment consultations that previously never reached it, and within six months the practice is reporting a significant increase in appointment demand without any increase in clinical resource. This is precisely the dynamic examined in our earlier analysis of the real state of British primary care, where the waiting room figures mask a far deeper capacity crisis. Pharmacy closures are accelerants to a fire that was already burning.

    Is the NHS funding model structurally broken for this purpose?

    The honest answer is yes, and has been for some time. The NHS community pharmacy contract was designed in an era of lower labour costs, lower property costs, and a wholesale reimbursement model that actually covered the cost of drugs. All three of those assumptions have collapsed. The reimbursement system has a particular absurdity at its core: pharmacies are paid a fixed dispensing fee per item rather than a fee that reflects the actual time and clinical complexity involved. A pharmacist who spends eight minutes counselling a recently discharged patient on a complex new regimen is paid the same as one who slaps a label on a box of antihistamines. The Pharmacy First scheme, launched in 2024, was supposed to begin rebalancing this by paying for clinical consultations directly. The scheme has genuine merit but has been funded at a level that industry bodies describe, charitably, as insufficient to reverse structural decline.

    The government’s position, when pressed, tends to oscillate between acknowledging the problem and pointing to Pharmacy First as evidence of commitment. What it does not acknowledge is that the core contract funding gap is so large that even a well-designed consultation service cannot compensate for dispensing fees that have not kept pace with inflation for a decade. This is analogous to the situation facing other community infrastructure built on underfunded assumptions, where the gap between what a service costs to run and what the state is willing to pay has simply become untenable.

    The elderly population carries the greatest burden

    Over-65s account for roughly 66% of all prescription items dispensed in England, according to ONS data. They are also disproportionately concentrated in rural and coastal areas, precisely where community pharmacy closures are hitting hardest. For many of these patients, the pharmacist is the most frequent clinical contact they have, more frequent than the GP and immeasurably more accessible than a hospital specialist. The loss of that contact is not neutral. Medication adherence falls when patients cannot get informal support with their prescriptions. Hospital admissions for medication-related errors tend to rise in areas with reduced pharmacy access. These are not predictions; they are outcomes that have been documented in peer-reviewed literature on pharmacy deserts in comparable health systems.

    The connection to broader workforce pressures is also worth flagging. As I noted in the piece on long-term sickness and workforce inactivity, Britain already has a significant population managing chronic conditions without adequate clinical support. Community pharmacists have historically been part of the management infrastructure for those conditions. Their disappearance does not make the chronic conditions go away; it makes them worse and more expensive to treat.

    What a credible fix would actually require

    The PSNC and various health think tanks have been fairly consistent about the broad shape of what is needed: a genuine real-terms uplift to the core dispensing contract, a protected rural pharmacy designation with additional funding for low-volume dispensing sites, and a formal commissioning framework that recognises pharmacists as primary care clinicians rather than drug retailers who happen to be convenient. The total cost of doing this properly is estimated at somewhere between £600 million and £800 million annually above current settlement levels. That sounds large until you set it against the downstream cost of redirecting thirty-five million consultations into general practice and emergency departments that are already at breaking point.

    The political will, so far, has not been there. Pharmacy closures generate less outrage than A&E closure threats, in part because they happen one at a time, in small places, to people who do not have the organisational capacity to protest loudly. The last chemist in a market town closes on a Friday afternoon; by Monday, the story has moved on. But the cumulative effect of a thousand such Fridays is a healthcare system that is materially less capable of keeping its most vulnerable patients safe. That is the story, and it is not a small one.

    Frequently Asked Questions

    How many community pharmacies have closed in England recently?

    England lost more than 1,100 community pharmacies between 2017 and 2025, with closures continuing to outpace new openings in 2025 and into 2026. Rural and coastal areas have been hit hardest, where independent operators have the least financial cushion to absorb the gap between NHS reimbursement and actual operating costs.

    Why are community pharmacies closing in the UK?

    The primary cause is a core NHS dispensing contract that has not received a meaningful real-terms funding increase since 2015, while wage costs, National Insurance contributions and energy bills have all risen sharply. Independent pharmacy owners are effectively subsidising NHS services from their own income until they can no longer afford to, at which point closure is the only option.

    What happens to patients when their local pharmacy closes?

    Patients are typically directed to online prescription services or the nearest remaining pharmacy, which may be several miles away. For elderly or less mobile patients this creates serious problems with medication adherence and loss of the informal clinical triage that pharmacists provide. Evidence suggests GP appointments and A&E attendances increase in areas that lose pharmacy access.

    What is the NHS Pharmacy First scheme and does it help?

    Pharmacy First, launched in 2024, allows community pharmacists to assess and treat patients for seven common conditions without a GP referral, and pays a direct consultation fee for doing so. Industry bodies broadly welcome the scheme’s design but argue the funding attached to it is insufficient to offset the structural losses caused by the underfunded dispensing contract.

    Are rural pharmacies more at risk of closing than urban ones?

    Yes, significantly so. Urban pharmacies can generate revenue from over-the-counter sales and private services that cross-subsidise low NHS reimbursement rates. Rural pharmacies serving small, dispersed populations depend almost entirely on the NHS contract, which means they are the first to become unviable when that contract fails to cover operating costs.

  • The Invisible Illness Driving Britain’s Workplace Absence Crisis: What the Surge in Long-Term Sickness Actually Tells Us

    The Invisible Illness Driving Britain’s Workplace Absence Crisis: What the Surge in Long-Term Sickness Actually Tells Us

    There is a number that the Treasury keeps returning to, and it is becoming harder to explain away. Around 2.8 million people in Britain are currently out of work due to long-term sickness, a figure that has climbed, almost without pause, since the start of 2020. According to the Office for National Statistics, long-term sickness is now the single largest reason for economic inactivity among working-age adults in the UK, overtaking retirement, caring responsibilities and study. That is a significant structural shift, and I’d argue we are only beginning to reckon with what it means.

    The conditions driving this surge are not the ones you might expect from a Victorian-era conception of workplace incapacity. This is not a story about industrial accidents or occupational lung disease. The fastest-growing categories are mental health conditions, chronic pain syndromes and post-viral illness, including Long Covid. Put simply, Britain’s workforce is becoming less healthy in ways that are difficult to see, difficult to measure and, for those experiencing them, frequently disbelieved.

    Man sitting exhausted at home, representing long-term sickness UK workforce inactivity
    Photo by SHVETS production on Pexels

    What the DWP and ONS figures actually show

    The Department for Work and Pensions publishes regular statistics on health-related benefits, and the trajectory is stark. Claims for Personal Independence Payment and its predecessor Disability Living Allowance have risen sharply, with mental and behavioural disorders now accounting for around 35% of all new PIP claims. The ONS Labour Force Survey, which captures economic inactivity more broadly, shows that the share of 16-to-64-year-olds citing long-term illness as their reason for not working has risen by roughly a third since 2019.

    What makes this particularly thorny for policymakers is the age distribution. This is not exclusively a crisis of older workers approaching retirement. A substantial and growing proportion of those leaving the workforce due to ill health are in their thirties and forties. The Resolution Foundation estimated in late 2024 that the UK has a higher rate of working-age economic inactivity due to ill health than comparable European economies, including France, Germany and the Netherlands. That gap is widening, not narrowing.

    I’ve spoken to several GPs and occupational health specialists over the past year, and the picture they describe from inside consulting rooms is consistent with the headline data. Waiting lists for mental health services remain long enough that people deteriorate before they receive treatment. Chronic pain, which the British Pain Society estimates affects around 28 million adults in the UK, is still treated with considerable scepticism in both clinical and workplace settings. And Long Covid, affecting an estimated 1.8 million people according to ONS self-reported data from 2025, has created an entirely new cohort of working-age adults unable to sustain full-time employment.

    Why mental health conditions are driving the headline numbers

    Anxiety, depression and related conditions have become the dominant diagnostic category within long-term sickness UK workforce inactivity, and the reasons are not difficult to identify even if the remedies are elusive. The pandemic, the cost-of-living crisis and years of wage stagnation have created conditions under which mental health problems flourish. The NHS mental health waiting list in England alone ran to over 1.6 million people earlier this year.

    The problem is self-reinforcing. When someone leaves work due to depression or anxiety, the loss of routine, social contact and financial security tends to deepen the original condition. Getting back into employment becomes harder with each passing month. The DWP’s own commissioned research has found that the longer someone is out of work due to mental illness, the less likely they are to return, regardless of the support they receive. This is a feedback loop that current policy instruments are poorly designed to break.

    There is also a class dimension that rarely receives the attention it deserves. Mental health conditions are more prevalent and more severe among people in lower-income households, those in insecure employment and those who have experienced housing instability. The idea that long-term sickness is distributed evenly across the workforce is simply not supported by the data. Those whose jobs offer flexibility, autonomy and adequate sick pay are considerably more likely to recover and return. Those whose jobs offer none of those things are considerably more likely to fall off the employment cliff entirely.

    The public finances arithmetic is brutal

    The fiscal consequences are substantial. The Office for Budget Responsibility has repeatedly flagged health-related inactivity as a structural risk to the public finances, and for good reason. Each person who moves from employment to long-term sickness inactivity represents a swing in the government’s accounts: lost income tax and National Insurance receipts, plus the cost of health and disability benefits. The OBR estimated in its most recent Fiscal Risks report that the welfare bill relating to health conditions could rise by tens of billions of pounds over the next decade if current trends persist.

    Ministers have talked about reforming the work capability assessment and tightening eligibility for health-related benefits, and there is a real debate to be had about whether the current system creates any perverse incentives. But the people I’ve read about and spoken with who have left work due to chronic pain or severe anxiety are not, in the main, gaming a system. They are, by and large, genuinely unwell in ways that make sustained employment impossible without proper treatment and workplace accommodation. Cutting their income does not cure their illness; it simply makes them poorer and sicker.

    The more honest question is whether the UK’s healthcare infrastructure is capable of treating these conditions at the scale now required. The NHS’s Talking Therapies programme has expanded, but referral-to-treatment times for more complex mental health presentations remain long. Occupational health provision is largely absent from small and medium-sized employers, who collectively employ the majority of the private-sector workforce. And post-viral illness services have been chronically underfunded relative to the scale of the problem they are supposed to address.

    What a serious response would look like

    A genuine strategy to reduce long-term sickness UK workforce inactivity would need to operate on several fronts simultaneously. Earlier clinical intervention, before conditions become entrenched, is the most obvious lever. Expanding access to occupational health assessment, particularly for workers in small businesses, would help retain people in work before they reach crisis point. Reforming statutory sick pay so that lower-paid workers are not financially compelled to return to work before they are ready would reduce the number of people who deteriorate after a premature return.

    Flexible working, which has been shown to support people with chronic conditions, should be a meaningful right rather than the nominal one it currently is. The challenges facing older workers managing health conditions have been well-documented, and the same workplace adaptations that benefit those in their sixties are equally valuable for someone in their forties managing chronic pain. There is also a conversation to be had about the quality of work on offer. Precarious, high-pressure, low-autonomy employment is itself a driver of the mental health conditions that are now emptying the workforce. You cannot solve a public health problem by ignoring its structural causes.

    The broader context matters here too. Britain’s working-age population is becoming less healthy against a backdrop of a pension system already under significant strain and a welfare state that is not designed to absorb this volume of need. And as explored in our recent piece on developmental disruption in schools, many of the risk factors for poor adult mental health are being set in childhood. The sickness crisis in the workforce is not a discrete policy problem. It is a symptom of something larger and considerably harder to fix.

    I am not optimistic that the current political environment, with its focus on benefits reform and fiscal consolidation, will produce the sustained investment that a genuine solution requires. But the data is unambiguous. Britain is losing hundreds of thousands of working-age people to preventable and treatable conditions, at enormous cost to those individuals and to the public finances. Looking away from that because the conversation is uncomfortable is no longer a viable position.

    Frequently Asked Questions

    How many people in the UK are out of work due to long-term sickness?

    Approximately 2.8 million working-age adults in the UK are currently economically inactive due to long-term sickness, according to ONS Labour Force Survey data. This figure has risen substantially since 2019 and represents the single largest category of economic inactivity.

    What conditions are most commonly behind long-term sickness UK workforce inactivity?

    Mental health conditions including anxiety and depression are the fastest-growing category, followed by musculoskeletal problems and chronic pain. Post-viral illness, particularly Long Covid, has added a significant new cohort since 2020, with ONS estimating around 1.8 million people in the UK reporting Long Covid symptoms in 2025.

    How much does long-term sickness inactivity cost the UK public finances?

    The Office for Budget Responsibility has flagged health-related inactivity as a structural fiscal risk, estimating the welfare bill for health conditions could rise by tens of billions of pounds over the next decade. The cost includes both reduced tax receipts and increased spending on disability and health benefits.

The Latest